Nanostructured Systems Containing Rutin: In Vitro Antioxidant Activity and Photostability Studies
© The Author(s) 2010
Received: 7 May 2010
Accepted: 30 June 2010
Published: 15 July 2010
The improvement of the rutin photostability and its prolonged in vitro antioxidant activity were studied by means of its association with nanostructured aqueous dispersions. Rutin-loaded nanocapsules and rutin-loaded nanoemulsion showed mean particle size of 124.30 ± 2.06 and 124.17 ± 1.79, respectively, polydispersity index below 0.20, negative zeta potential, and encapsulation efficiency close to 100%. The in vitro antioxidant activity was evaluated by the formation of free radical ·OH after the exposure of hydrogen peroxide to a UV irradiation system. Rutin-loaded nanostructures showed lower rutin decay rates [(6.1 ± 0.6) 10−3 and (5.1 ± 0.4) 10−3 for nanocapsules and nanoemulsion, respectively] compared to the ethanolic solution [(35.0 ± 3.7) 10−3 min−1] and exposed solution [(40.1 ± 1.7) 10−3 min−1] as well as compared to exposed nanostructured dispersions [(19.5 ± 0.5) 10−3 and (26.6 ± 2.6) 10−3, for nanocapsules and nanoemulsion, respectively]. The presence of the polymeric layer in nanocapsules was fundamental to obtain a prolonged antioxidant activity, even if the mathematical modeling of the in vitro release profiles showed high adsorption of rutin to the particle/droplet surface for both formulations. Rutin-loaded nanostructures represent alternatives to the development of innovative nanomedicines.
KeywordsAntioxidant activity Nanocapsules Nanoemulsions Nanoparticles Photostability Rutin
Currently, there is a growing interest in the study of antioxidants [1, 2]. Recent discoveries have pointed out the effects of free radicals in the body, which are involved in energy production, phagocytosis, and regulation of cell growth among others . Oxidative stress is a condition that occurs in a system when the generation of reactive oxygen species exceeds the capacity of neutralization and disposal system. The instability may result from a lack of antioxidant capacity caused by disturbances in the production, distribution, or by an abundance of reactive oxygen species from endogenous sources or stressful environmental conditions. Oxidative stress has been implicated in a growing list of diseases such as cardiovascular and neurodegenerative diseases, cancer, arthritis, hemorrhagic shock, cataracts, as well as in aging processes [3–5].
Among the various classes of antioxidants, naturally occurring phenolic compounds have received much attention in recent years due to their inhibition of lipid peroxidation and lipoxygenase . The antioxidant activity of phenolic compounds is mainly related to their reducing properties and chemical structure . These characteristics play an important role in the neutralization or sequestration of free radicals and chelation of transition metals, acting both in the initiation step and in the propagation of oxidation . The intermediate species formed by the action of antioxidant phenolic compounds are relatively stable due to the resonance of the aromatic ring in their structure .
Natural flavonoids are phenolic compounds known for their significant scavenging properties on oxygen radicals both in vivo and in vitro [8, 9]. Many studies have showed the importance of their antiradical activity [10–13]. Moreover, their actions in humans have been subject of extensive research, and natural flavonoids have been described to possess several biological activities such as antioxidant, anti-inflammatory, antitumor, and antiviral properties .
Rutin (quercetin-3-O-rutinoside), the glycoside of quercetin, is abundantly found and distributed in plants such as in buckwheat seed, fruits, and fruit rinds, especially citrus fruits (orange, grapefruit, lemon). It presents important properties in human health like its significant scavenging properties on oxidizing species such as hydroxyl radical, superoxide radical, and peroxyl radical , as shown by many in vitro and in vivo experiments [16–18]. Furthermore, rutin has several pharmacological activities including anti-allergic, anti-inflammatory, and vasoactive properties [15, 19, 20]. Rutin offers an advantage over other flavonoids, which in some occasions behave as pro-oxidant agents and catalyze oxygen production . Therefore, it is considered a non-toxic molecule and not oxidized. On the other hand, the main disadvantage of the molecule is its poor solubility in aqueous media, explaining its poor oral or topical bioavailability  and being a drawback to its conversion in adequate dosage forms.
In the last decade, an alternative drug delivery approach was developed to overcome the poor water solubility of rutin by reducing its particle size . A decrease in the drug particle size leads to an increase in the saturation solubility, to an enlarged surface area and to a higher dissolution velocity . Formulating rutin as drug nanocrystals has significant importance to improve its physicochemical properties, especially its oral bioavailability. Some studies have shown techniques for lyophilization and spray drying nanocrystals of rutin in order to ensure their redispersibility as separate and non-aggregated particles. This characteristic is a critical point to improve the dissolution behavior of drugs, especially from a tablet dosage form [19, 20].
On the other hand, polymeric nanoparticles have been designed to encapsulate lipophilic drugs not only to improve their physicochemical properties but also to target organs or tissues, to avoid drug degradation, to improve drug efficacy, and to circumvent drug toxicity . Nanocapsules are polymeric nanoparticles composed of an oily core surrounded by a polymeric wall stabilized by surfactants at the particle/water interface . The potential use of nanocapsules includes the protection of drugs against inactivation in the gastrointestinal tract , delivery of poorly water-soluble compounds [24, 25], and protection of sensitive materials to chemical degradation induced by UV light [26–28]. As the polymeric nanoparticles, nanoemulsions have been also investigated as drug delivery systems in the last years [29–32]. These colloidal systems are composed of oily nanodroplets stabilized by surfactants in an aqueous medium.
All these considerations into account, the main objective of our study was to develop aqueous rutin delivery systems and to evaluate the influence of the association of rutin to different nanostructures (nanocapsules and nanoemulsions) on its in vitro antioxidant activity and UV photostability. Nanocapsules and nanoemulsions were compared to establish the importance of the polymeric layer around the nanodroplets by means of a systematic physicochemical characterization of both formulations. The development of such formulations aimed to obtain aqueous systems containing rutin, as an intermediate or final pharmaceutical product. To the best of our knowledge, no report on the association of rutin to polymeric nanocapsules is currently available in the scientific literature. The administration of flavonoids by means of nanovectors may be useful for the development of advanced delivery systems for these powerful compounds, in view of their adoption in primary and secondary disease prevention, either for oral or parenteral administration .
Materials and Methods
Rutin, poly-(ε-caprolactone) (PCL), and sorbitan monostearate (Span 60®) were acquired from Sigma–Aldrich (São Paulo, Brazil). Polysorbate 80 (Tween 80®) was supplied by Henrifarma (São Paulo, Brazil). Grape seed oil was obtained from Dellaware (Porto Alegre, Brazil). All other chemicals and solvents presented pharmaceutical or HPLC grade and were used as received.
Preparation of Nanoparticles
List of nomenclatures presented in tables and figures
Blank nanocapsules (nanocapsules prepared without drug)
Blank nanoemulsion (nanoemulsion prepared without drug)
Rutin ethanolic solution
Release rate constant according (monoexponential kinetic)
Release rate constant of the burst phase (biexponential kinetic)
Release rate constant of the sustained phase (biexponential kinetic)
Initial concentration of rutin at the burst phase (biexponential kinetic)
Initial concentration of rutin at the sustained phase (biexponential kinetic)
Model selection criteria
Characterization of Nanoparticles
Rutin was assayed by liquid chromatography (LC). The chromatographic system consisted of a Gemini RP-18 column (150 × 4.60 mm, 5 μm, Phenomenex, Torrance, USA) and a Shimadzu instrument (LC-10AVP Pump, UV–VIS SPD-10AVP Module, Class-VP Software, Shimadzu, Tokyo, Japan). The mobile phase consisted of methanol/water (50:50% v/v) acidified with phosphoric acid (apparent pH 4.0) pumped at a flow rate of 1.0 ml min−1. The volume injected was 20 μl, and rutin was detected at 352 nm. Rutin content (mg ml−1) was determined (n = 3) after its extraction with methanol from nanocapsules or nanoemulsions (1.6 ml of the formulation to 10 ml of methanol) and dilution with the mobile phase to a concentration of 20 μg ml−1. Validation of the LC assay demonstrated that this method was linear (y = 30,322× – 6,233.7, r = 0.9999, n = 5) in the range of 5–30 μg ml−1, precise (RSD: 1.86% for repeatability and 0.70% for intermediate precision) and accurate (RSD: 1.70%). The specificity was tested in presence of the nanoparticle adjuvants and demonstrated that they did not alter the rutin assay .
Free rutin was determined in the ultrafiltrate after separation of the nanoparticles by ultrafiltration/centrifugation technique (Microcon 10,000 MW, Millipore). Encapsulation efficiency (%) was calculated by the difference between the total and free rutin concentrations determined in the nanoparticles (drug content) and in the ultrafiltrate, respectively, using the LC method previously described.
The pH values of formulations were determined by immersion of the electrode directly in the dispersions using a calibrated potentiometer (MPA-210 Model, MS-Tecnopon, São Paulo, Brazil), at room temperature.
Particle Size Analysis, Polydispersity Indices, and Zeta Potential
Particle sizes and polydispersity indices (n = 3) were measured by photon correlation spectroscopy after adequate dilution of an aliquot of the suspension in reverse osmosis water (Brookhaven Instruments Corporation, USA). The zeta potentials were determined after dilution of the samples in 10 mM NaCl aqueous solution (Brookhaven Instruments Corporation, Holtsville, USA).
Morphological analyses were conducted at Centro de Microscopia (UFRGS, Brazil) by transmission electron microscopy (TEM; Jeol, JEM 1200 Exll, Japan) operating at 80 kV. Diluted suspensions and nanoemulsions were deposited on specimen grid (Formvar-Carbon support films, Electron Microscopy Sciences), negatively stained with uranyl acetate solution (2% w/v)  and observed at different magnifications.
Antioxidant Activity and Photostability Study
where k OH + hv represents the kinetic constant determined by the rutin decay after UV photolysis in the presence of H2O2 k hv represents the kinetic constant determined by the direct photolysis of rutin in absence of H2O2, and k OH represents the liquid free radical reaction kinetic constant of the ·OH radical with the antioxidant.
In Vitro Rutin Release Assay
In vitro drug release profiles from rutin-loaded nanostructures were evaluated (n = 3) by the dialysis bag method, using water/ethanol (65:35 v/v) as medium, at 37°C . The dialysis bag (Spectra Por 7, 10 Kd, Biosystems) containing 1 ml of the sample (0.25 mg ml−1) was put into a glass test-tube containing 200 ml of dissolution medium. This system was maintained under constant moderate stirring during all the time. The withdrawal of 2 ml of the external medium from the system was done at predetermined time interval, replaced by an equal volume of fresh medium, and filtered through a 0.45-μm membrane. Rutin was assayed in the samples by LC according to the method previously described. However, the injection sample volume was increased to 100 μl to allow the assay of rutin at lower concentrations. This LC method was validated according to the following characteristics: linearity (y = 167,806× + 1,170.3, n = 3, r = 0.9997), concentration range (0.1–2.0 mg ml−1), and precision (RSD: 0.90%).
In order to obtain a better understanding of the influence of the type of nanoparticle structure on the rutin release behavior, the mathematical modeling (MicroMath® Scientist® for Windows) was used to analyze the drug release profiles. Monoexponential (C = C0e−kt) and biexponential (C = ae−k 1 t + be−k 2 t) models were used to evaluate the rutin release profiles. The release rate constants are k, k 1, and k 2 and the initial concentration of rutin are C 0, a, and b. The selection of the model that best fit the release profiles was based on the best correlation coefficient, the best model selection criteria (MSC), both provided by the software and the best graphic adjustment. The meaning of all these abbreviations is presented in Table 1.
Formulations were prepared and analyzed in triplicate. Results are expressed as mean ± SD (standard deviation). Two-way analysis of variance (ANOVA) was employed in the comparison of the experimental data. Post hoc multiple comparisons were done by Tukey’s test for significance at p–values ≤ 0.05. All analyses were run using the SigmaStat Statistical Program (Version 3.0, Jandel Scientific, USA).
Results and Discussion
Preparation and Physicochemical Characterization of Aqueous Nanostructured Systems
Drug content, encapsulation efficiency, and pH of rutin-loaded nanocapsules (R-NC) and rutin-loaded nanoemulsion (R-NE) as well as their respective blank formulations (B-NC and B-NE) (n = 3)
Drug content (mg ml−1)
Encapsulation efficiency (%)
5.79 ± 0.03
0.25 ± 0.01
93.33 ± 0.63
5.69 ± 0.08
5.94 ± 0.10
0.24 ± 0.01
93.83 ± 0.41
5.59 ± 0.01
Particle size, polydispersity index, and zeta potential of rutin-loaded nanocapsules (R-NC) and rutin-loaded nanoemulsion (R-NE) as well as their respective blank formulations (B-NC and B-NE) (n = 3)
Particle size (nm)
Zeta potential (mV)
120.37 ± 2.44
0.11 ± 0.06
−20.55 ± 3.63
124.30 ± 2.06
0.12 ± 0.02
−27.12 ± 9.19
128.06 ± 3.38
0.13 ± 0.03
−26.03 ± 2.27
124.17 ± 1.79
0.10 ± 0.02
−26.92 ± 1.45
Antioxidative Activity, UV Protodegradation, and In Vitro Release Assay
Rate constants, correlation coefficients, and MSC obtained by the mathematical modeling of drug release data from the different nanocarriers (R-NC and R-NE)
0.3215 ± 0.0674
0.4336 ± 0.0242
0.9979 ± 0.0010
0.9983 ± 0.0016
2.9935 ± 0.2326
3.0585 ± 0.9828
k 1 (h−1)
0.4113 ± 0.0765
0.8164 ± 0.6039
k 2 (h−1)
0.0310 ± 0.0163
0.1393 ± 0.1993
a (mg ml−1)
0.8447 ± 0.0597
0.6107 ± 0.3337
b (mg ml−1)
0.1285 ± 0.0370
0.3201 ± 0.4125
0.9997 ± 0.0002
0.9994 ± 0.0006
6.5420 ± 0.5612
6.0185 ± 0.8945
The rate constants for the burst phase (k 1) were 0.4113 ± 0.0765 h−1 (R-NC) and 0.8164 ± 0.6039 h−1 (R-NE) and for the sustained phase the rate constants (k 2) were 0.0310 ± 0.0163 (R-NC) and 0.1393 ± 0.1993 h−1 (R-NE). For both phases, R-NC showed lower rate constants compared to R-NE. The percentage of rutin related the burst phase (a) for nanocapsules and nanoemulsions was about 85 and 65%, respectively. On the other hand, the percentage related to the sustained phase was about 13% for R-NC and 32% for the R-NE. Such values showed that rutin is about 60–80% adsorbed on the surface of nanostructures [41, 42], suggesting that the radical scavenging property of rutin against the ·OH radical occurred mostly at the interface particle/water. However, the influence of the drug release from the inner compartment of the nanocarriers cannot be discarded, considering the slower drug release rate from R-NC at both release phases. This hypothesis can be reinforced by the analysis of the release half-life of rutin, calculated according to the biexponential model. R-NC showed higher values (1.7 and 22 h for the burst and sustained phase, respectively) compared to R-NE (0.8 and 5 h for the burst and sustained phase, respectively). This faster drug release from R-NE can be explained by the absence of the polymer around the oily droplets as well as by the presence of nanocrystals on their surface, as observed by TEM.
This study showed for the first time the development of rutin-loaded nanocapsules and nanoemulsions, as aqueous intermediate or final systems to the development of nanomedicines containing rutin. Both formulations presented an increase in the rutin photostability and a prolonged in vitro antioxidant activity, even if the main mechanism of association of rutin was the adsorption on the particle/droplet surface, as determined by the mathematical modeling of drug release data. Moreover, the presence of polymer did not show any significant influence in the increase of rutin photostability. However, its presence in nanocapsules led to a slower release rate and to a prolonged antioxidant activity against the strongly reactive ·OH radicals compared to the rutin-loaded nanoemulsions. The results showed that such nanostructured systems are a potential alternative to the preparation of rutin delivery systems to treat different diseases related to oxidative stress, including aging processes caused by the action of free radicals.
JSA thanks CAPES/Brazil for the fellowship. We thank Rede Nanocosméticos CNPq/MCT/Brazil, PRONEX/FAPERGS/CNPq, CAPES and CNPq for the financial support received as well as M.B. da Rosa for his contribution in this work.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- Sousa CMM, Rocha e Silva H Jr., Vieira GM, Ayres MCC, Costa CLS, Araújo DS, Cavalcante LCD, Barros EDS, Araújo PBM, Brandão MS, Chaves MH: Quim. Nova. 2007, 30: 351. COI number [1:CAS:528:DC%2BD2sXjtlGlt7Y%3D] COI number [1:CAS:528:DC%2BD2sXjtlGlt7Y%3D] 10.1590/S0100-40422007000200021View ArticleGoogle Scholar
- Darvesh AS, Carroll RT, Bishayee A, Geldenhuys WJ, Van der Schyf CJ: Expert Rev. Neurother.. 2010, 10: 729. COI number [1:CAS:528:DC%2BC3cXlsVWlsrk%3D] COI number [1:CAS:528:DC%2BC3cXlsVWlsrk%3D] 10.1586/ern.10.42View ArticleGoogle Scholar
- Barreiros ALBS, David JM: Quim. Nova. 2006, 29: 113. COI number [1:CAS:528:DC%2BD28XhvVKqtbg%3D] COI number [1:CAS:528:DC%2BD28XhvVKqtbg%3D] 10.1590/S0100-40422006000100021View ArticleGoogle Scholar
- Brenneisen P, Steinbrenner H, Sies H: Mol. Aspects Med.. 2005, 26: 256. COI number [1:CAS:528:DC%2BD2MXpslygtbo%3D] COI number [1:CAS:528:DC%2BD2MXpslygtbo%3D] 10.1016/j.mam.2005.07.004View ArticleGoogle Scholar
- Cornelli U: Clin. Dermatol.. 2009, 27: 175. 10.1016/j.clindermatol.2008.01.010View ArticleGoogle Scholar
- Michalak A: Polish J. Environ. Stud.. 2006, 15: 523. COI number [1:CAS:528:DC%2BD28Xps1Cmtb8%3D] COI number [1:CAS:528:DC%2BD28Xps1Cmtb8%3D]Google Scholar
- Chun SS, Vatem DA, Lin YT, Shetty K: Process Biochem.. 2005, 40: 809. COI number [1:CAS:528:DC%2BD2cXpt1Wgtrk%3D] COI number [1:CAS:528:DC%2BD2cXpt1Wgtrk%3D] 10.1016/j.procbio.2004.02.018View ArticleGoogle Scholar
- Abad MJ, Bermejo P, Villar A: Gen. Pharmacol.. 1995, 26: 815. COI number [1:CAS:528:DyaK2MXlsFSktbk%3D] COI number [1:CAS:528:DyaK2MXlsFSktbk%3D] 10.1016/0306-3623(94)00242-FView ArticleGoogle Scholar
- La Casa C, Villegas I, de la Lastra CA, Motilva V, Martín Calero MJ: J. Ethnopharmacol.. 2000, 71: 45. COI number [1:CAS:528:DC%2BD3cXkvFSgtr8%3D] COI number [1:CAS:528:DC%2BD3cXkvFSgtr8%3D] 10.1016/S0378-8741(99)00174-9View ArticleGoogle Scholar
- Solomon A, Golubowicz S, Yablowicz Z, Bergman M, Grossman S, Altmann A, Kerem Z, Flaishman MA: J. Agric. Food Chem.. 2010, 58: 6660. COI number [1:CAS:528:DC%2BC3cXls1Shuro%3D] COI number [1:CAS:528:DC%2BC3cXls1Shuro%3D] 10.1021/jf100122aView ArticleGoogle Scholar
- Krishna KL, Mruthunjaya K, Patel JA: Int. J. Pharmacol.. 2010, 6: 72. 10.3923/ijp.2010.72.80View ArticleGoogle Scholar
- Fawole OA, Amoo SO, Ndhlala AR, Light ME, Finnie JF, Van Staden J: J. Ethnopharmacol.. 2010, 127: 235. COI number [1:STN:280:DC%2BC3c%2FnsVOhug%3D%3D] COI number [1:STN:280:DC%2BC3c%2FnsVOhug%3D%3D] 10.1016/j.jep.2009.11.015View ArticleGoogle Scholar
- Jiang H, Zhan WQ, Liu X, Jiang SX: Nat. Prod. Res.. 2008, 22: 1650. COI number [1:CAS:528:DC%2BD1MXptVGruw%3D%3D] COI number [1:CAS:528:DC%2BD1MXptVGruw%3D%3D] 10.1080/14786410701875686View ArticleGoogle Scholar
- Yang J, Guo J, Yuan J: LWT. 2008, 41: 1066. 10.1016/j.lwt.2007.06.010View ArticleGoogle Scholar
- Calabrò ML, Tommasini S, Donato P, Stancanelli R, Raneri D, Catania S, Costa C, Villari V, Ficarra P, Ficarra R: J. Pharm. Biomed. Anal.. 2005, 36: 1019. 10.1016/j.jpba.2004.09.018View ArticleGoogle Scholar
- Korkmaz A, Kolankaya D, Surg J: Res. 2009. 10.1016/j.jss.2009.03.022Google Scholar
- Verma AR, Vijayakumar M, Mathela CS, Rao CV: Food Chem. Toxicol.. 2009, 47: 2196. COI number [1:CAS:528:DC%2BD1MXps1eqsrc%3D] COI number [1:CAS:528:DC%2BD1MXps1eqsrc%3D] 10.1016/j.fct.2009.06.005View ArticleGoogle Scholar
- Itagaki S, Oikawa J, Ogura J, Kobayashi M, Hirano T, Iseki K: Food Chem.. 2010, 118: 426. COI number [1:CAS:528:DC%2BD1MXhtVaru7bE] COI number [1:CAS:528:DC%2BD1MXhtVaru7bE] 10.1016/j.foodchem.2009.04.103View ArticleGoogle Scholar
- Mauludin R, Müller RH, Keck CM: Int. J. Pharm.. 2009, 370: 202. COI number [1:CAS:528:DC%2BD1MXislKisbY%3D] COI number [1:CAS:528:DC%2BD1MXislKisbY%3D] 10.1016/j.ijpharm.2008.11.029View ArticleGoogle Scholar
- Mauludin R, Müller RH, Keck CM: Eur. J. Pharm. Sci.. 2009, 36: 502. COI number [1:CAS:528:DC%2BD1MXhs1aqtbc%3D] COI number [1:CAS:528:DC%2BD1MXhs1aqtbc%3D] 10.1016/j.ejps.2008.12.002View ArticleGoogle Scholar
- Couvreur P, Barrat G, Fattal E, Legrand P, Vauthier C: Ther. Drug Carrier Syst.. 2002, 19: 99. COI number [1:CAS:528:DC%2BD38XntFSksbg%3D] COI number [1:CAS:528:DC%2BD38XntFSksbg%3D] 10.1615/CritRevTherDrugCarrierSyst.v19.i2.10View ArticleGoogle Scholar
- Mora-Huertas CE, Fessi H, Elaissari A: Int. J. Pharm.. 2010, 385: 113. COI number [1:CAS:528:DC%2BD1MXhs1Sls7bJ] COI number [1:CAS:528:DC%2BD1MXhs1Sls7bJ] 10.1016/j.ijpharm.2009.10.018View ArticleGoogle Scholar
- Pohlmann AR, Weiss V, Mertins O, da Silveira NP, Guterres SS: Eur. J. Pharm. Sci.. 2002, 16: 305. 10.1016/S0928-0987(02)00127-6View ArticleGoogle Scholar
- Fachinetto JM, Ourique AF, Lubini G, Tedesco SB, Silva ACF, Beck RCR: Lat. Am. J. Pharm.. 2008, 27: 668. COI number [1:CAS:528:DC%2BD1MXisVKgsLc%3D] COI number [1:CAS:528:DC%2BD1MXisVKgsLc%3D]Google Scholar
- Teixeira M, Alonso MJ, Pinto MMM, Barbosa CM: Eur. J. Pharm. Biopharm.. 2005, 59: 491. COI number [1:CAS:528:DC%2BD2MXit1Chs74%3D] COI number [1:CAS:528:DC%2BD2MXit1Chs74%3D] 10.1016/j.ejpb.2004.09.002View ArticleGoogle Scholar
- Ourique AF, Pohlmann AR, Guterres SS, Beck RCR: Int. J. Pharm.. 2008, 352: 1. COI number [1:CAS:528:DC%2BD1cXitlWhsLs%3D] COI number [1:CAS:528:DC%2BD1cXitlWhsLs%3D] 10.1016/j.ijpharm.2007.12.035View ArticleGoogle Scholar
- Almeida JS, Jezur L, Fontana MC, Paese K, Silva CB, Pohlmann AR, Guterres SS, Beck RCR: Lat. Am. J. Pharm.. 2009, 28: 168.Google Scholar
- Fontana MC, Coradini K, Guterres SS, Pohlmann AR, Beck RCR: J. Nanosci. Nanotechnol.. 2010, 10: 3091. COI number [1:CAS:528:DC%2BC3cXjtlCrsL8%3D] COI number [1:CAS:528:DC%2BC3cXjtlCrsL8%3D] 10.1166/jnn.2010.1920View ArticleGoogle Scholar
- Schaffazick SR, Freitas LL, Pohlmann AR, Guterres SS: Quim. Nova. 2003, 25: 726.View ArticleGoogle Scholar
- Guterres SS, Alves MP, Pohlmann AR: Drug Target Insights. 2007, 2: 147.Google Scholar
- Pohlmann AR, Mezzalira G, De C, Venturini G, Cruz L, Bernardi A, Jäger E, Battastini AMO, da Silveira NP, Guterres SS: Int. J. Pharm.. 2008, 359: 288. COI number [1:CAS:528:DC%2BD1cXmvVems7o%3D] COI number [1:CAS:528:DC%2BD1cXmvVems7o%3D] 10.1016/j.ijpharm.2008.04.007View ArticleGoogle Scholar
- Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, Chen H, Sun H, Tian Y, Liu K, Li Z, Huang L: Nanoscale Res. Lett.. 2009, 4: 1530. COI number [1:CAS:528:DC%2BD1MXhsFWqsbfK]; Bibcode number [2009NRL.....4.1530M] COI number [1:CAS:528:DC%2BD1MXhsFWqsbfK]; Bibcode number [2009NRL.....4.1530M] 10.1007/s11671-009-9431-6View ArticleGoogle Scholar
- Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G: Curr. Med. Chem.. 2010, 17: 74. COI number [1:CAS:528:DC%2BC3cXhsVSmt7g%3D] COI number [1:CAS:528:DC%2BC3cXhsVSmt7g%3D] 10.2174/092986710789957760View ArticleGoogle Scholar
- Fessi H, Puisieux F, Devissaguet J-P: European Patent. 1988. 0274961 Al 0274961 AlGoogle Scholar
- Martini É, Carvalho E, Teixeira H: Quim. Nova. 2007, 30: 930. COI number [1:CAS:528:DC%2BD2sXotlOisr8%3D] COI number [1:CAS:528:DC%2BD2sXotlOisr8%3D] 10.1590/S0100-40422007000400032View ArticleGoogle Scholar
- 2005. ICH – International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Gudeline on Validation of Analytical Procedure Q2 (R1): Text and Methodology
- Beck RCR, Guterres SS, Funck JAB, Freddo RJ, Michalowski CB, Barcellos I: Acta Farm. Bonaer.. 2003, 22: 11. COI number [1:CAS:528:DC%2BD3sXjsFClu7o%3D] COI number [1:CAS:528:DC%2BD3sXjsFClu7o%3D]Google Scholar
- Carvalho LM, Spengler C, Garmatz JC, Nascimento PC, Bohrer D, Del-Fabro L, Radis G, Bolli AA, Moro AM, Garcia SC, Rosa MB: Quim. Nova. 2008, 31: 1336. 10.1590/S0100-40422008000600012View ArticleGoogle Scholar
- Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H: J. Control. Release. 2009, 133: 238. COI number [1:CAS:528:DC%2BD1MXpsF2kuw%3D%3D] COI number [1:CAS:528:DC%2BD1MXpsF2kuw%3D%3D] 10.1016/j.jconrel.2008.10.002View ArticleGoogle Scholar
- Friedrich RB, Fontana MC, Pohlmann AR, Guterres SS, Beck RCR: Quim. Nova. 2008, 31: 1131. COI number [1:CAS:528:DC%2BD1cXhtFSrsbrM] COI number [1:CAS:528:DC%2BD1cXhtFSrsbrM] 10.1590/S0100-40422008000500038View ArticleGoogle Scholar
- Cruz L, Soares LU, Dalla Costa T, Mezzalira G, Silveira NP, Guterres SS, Pohlmann AR: Int. J. Pharm.. 2006, 313: 198. COI number [1:CAS:528:DC%2BD28XjtVGqtbY%3D] COI number [1:CAS:528:DC%2BD28XjtVGqtbY%3D] 10.1016/j.ijpharm.2006.01.035View ArticleGoogle Scholar
- Fontana MC, Coradini K, Guterres SS, Pohlmann AR, Beck RCR: J. Biomedi. Nanotechnol.. 2009, 5: 254. COI number [1:CAS:528:DC%2BD1MXpsVGisrs%3D] COI number [1:CAS:528:DC%2BD1MXpsVGisrs%3D] 10.1166/jbn.2009.1030View ArticleGoogle Scholar